Breaking Trials & FDA Alerts: What Headlines Claim vs. What the Data Really Shows.

In the primary New England Journal of Medicine trial (PMID 37351564, N = 272) and companion Lancet diabetes trial (PMID 37364590, N = 383), daily oral orforglipron produced 9.4% to 14.7% body weight loss at 36 weeks (compared to 2.3% on placebo) and dropped HbA1c by up to 2.1 percentage points . That matches injectable semaglutide (Ozempic/Wegovy)! However, here is the honest catch: 10% to 17% of participants stopped taking the pill early because of nausea or vomiting, especially when the dose was stepped up too fast .

In the 13-year NIH Diabetes Prevention Program Outcomes Study (DPPOS, PMID 26900641, N = 2,155) and a 4.3-year randomized controlled trial in the BMJ (PMID 20488910, N = 390, NNT for deficiency = 14), long-term Metformin cut blood Vitamin B12 levels by an average of 19% and doubled the risk of clinical or borderline B12 deficiency . Even more striking: patients on Metformin who developed low B12 had significantly higher rates of peripheral neuropathy (numbness and tingling in the feet)—which can look identical to diabetic nerve damage unless somebody orders a simple $20 B12 blood test !